GIPR is an important metabolic receptor linking postprandial nutrient sensing, insulin secretion, and central regulation of food intake. Unlike most metabolic targets, enhancing GIPR signaling can contribute to weight loss, while reducing GIPR signaling can also enhance weight-loss effects. These two directions do not produce the same outcome through the same mechanism but instead involve different brain regions, neural circuits, and interactions with satiety signals such as GLP-1R. This bidirectional pharmacology is one of the most notable features of GIPR-targeted weight-loss research.

Keywords: GIPR; GIP; weight loss; GIPR agonist; GIPR antagonist; Tirzepatide; multi-receptor agonist

1 Physiological Basis of GIP and GIPR

1.1 Postprandial Nutrient Response of GIP

GIP is mainly released from intestinal K cells after food intake, and both glucose and lipids can stimulate its secretion. Native GIP is a typical postprandial nutrient signal that can enhance glucose-stimulated Insulin secretion and participate in postprandial nutrient handling. After entering the circulation, GIP can be rapidly cleaved by DPP-4, so endogenous GIP mainly produces short-duration, pulsatile receptor stimulation, which differs markedly from the sustained pharmacological exposure produced by long-acting GIPR agonists.

1.2 Activation of GIPR

(1) Ligand Binding and Receptor Conformational Change

GIPR belongs to the Class B1 G protein-coupled receptor family. The C-terminus of GIP mainly forms stable interactions with the extracellular domain of the receptor, while the N-terminus of the peptide further enters the transmembrane core region, promoting rearrangement of the transmembrane helices and stabilizing the active conformation, thereby creating an intracellular receptor structure favorable for G-protein binding.

(2) Activation of Gs-cAMP Signaling

Activated GIPR mainly couples to Gs proteins, promotes Adenylate Cyclase activation, and increases intracellular cAMP levels. cAMP further activates PKA and EPAC. In β cells, this enhances Ca²⁺-dependent secretory granule exocytosis, whereas in neurons it can alter membrane excitability, synaptic transmission, and neural-network output. The same proximal GIPR-Gs-cAMP signal can therefore generate different functional outcomes depending on the cell type.

(3) Receptor Desensitization and Trafficking

Sustained GIPR stimulation can induce receptor phosphorylation, changes in G-protein coupling efficiency, receptor internalization, and recycling, together with adaptation of intracellular cAMP-regulatory systems. The final pharmacological state of GIPR therefore depends not only on agonist intensity but also on the duration of stimulation and the cell type in which the receptor is expressed.

1.3 GIPR-Expressing Tissues Related to Weight Loss

The pancreatic islets and central nervous system are the two most important functional levels in GIPR-related weight-loss pharmacology. β-cell GIPR mainly regulates glucose-dependent Insulin secretion; GIPR in the brainstem and hypothalamus participates in hunger, satiety, and nutrient sensing; GIP-related signaling in adipose tissue also participates in postprandial fatty acid uptake, Triglyceride storage, and nutrient distribution. GIPR performs different functions in different tissues, so whole-body weight changes cannot be directly inferred from the effect observed in a single tissue.

2 Pharmacological Basis of Weight Loss Through GIPR Agonism

2.1 Promotion of Glucose-Dependent Insulin Secretion

(1) Enhancement of Ca²⁺-Dependent Insulin Granule Exocytosis

After GIP activates GIPR in β cells, intracellular cAMP levels increase. PKA can regulate voltage-dependent Ca²⁺ channels and secretion-related proteins, while EPAC participates in secretory granule mobilization and preparation for exocytosis, allowing more Insulin granules to enter a releasable state and increasing the efficiency of exocytosis after Ca²⁺ triggering.

(2) Amplification of Glucose-Triggered Secretory Signals

GIPR does not independently initiate the complete Insulin-release process. After Glucose enters β cells and metabolism raises the ATP/ADP ratio, KATP channels close, the cell membrane depolarizes, and Ca²⁺ influx is promoted; GIPR-cAMP signaling then further amplifies Insulin exocytosis on this basis. Under low-Glucose conditions, sufficient metabolic triggering is absent, and the insulinotropic effect of GIPR is correspondingly reduced.

2.2 Suppression of Food Intake and Enhancement of Satiety

Long-acting GIPR agonism can act on central GIPR neurons to reduce feeding drive and enhance satiety, and this effect is not entirely secondary to improved glucose control or changes in Insulin. Native GIP mainly produces transient postprandial signaling, whereas long-acting GIPR agonists markedly extend receptor-stimulation duration, converting a normally short-lived nutrient-feedback signal into more sustained pharmacological suppression of food intake.

3 Central GIPR and Mechanisms of Food-Intake Regulation

3.1 GABAergic GIPR Neurons

(1) Activation of Inhibitory Neural Networks

Some central GIPR is expressed in GABAergic neurons. After GIPR activation, cAMP-related signaling alters the excitability and synaptic output of these neurons, further adjusting inhibitory inputs within feeding networks. When GIPR function is reduced in GABAergic neurons, the food-intake suppression produced by long-acting GIPR agonists can be markedly weakened, indicating that this neuronal population is an important component of the central anorectic effect of GIPR.

(2) Remodeling of Feeding-Network Output

GABAergic GIPR neurons are not a single appetite switch but are connected with multiple neural networks involved in hunger drive, brainstem nutrient sensing, and postprandial satiety. GIPR activation alters the overall excitation-inhibition relationship of feeding networks and can simultaneously affect initiation, continuation, and termination of feeding.

3.2 Area Postrema-Related Feeding Circuits

The Area Postrema is located in a region where the blood-brain barrier is relatively permeable, allowing circulating peptide hormones and peripherally administered peptide drugs to access this brain region relatively easily. The AP and Nucleus Tractus Solitarius jointly integrate gastrointestinal, vagal, and circulating hormonal signals and participate in satiety, termination of feeding, and visceral sensation. Hindbrain GIPR, especially AP-related GIPR, is an important central node through which long-acting GIPR agonists directly suppress food intake.

3.3 Hypothalamic Energy-Balance Networks

The hypothalamus continuously integrates energy-related information from Leptin, Insulin, gastrointestinal hormones, and circulating nutrients. In addition to receiving GIP input, hypothalamic GIPR can alter the effective gain of other satiety signals within neural networks. Mouse studies indicate that AP-related GIPR more prominently mediates the direct food-intake suppression produced by long-acting GIPR agonists, whereas hypothalamic GIPR mediates the enhancement of weight-loss responses to GLP-1R and amylin receptor agonists during GIPR antagonism.

4 GIPR and Energy Storage in Adipose Tissue

4.1 Physiological GIP Participates in Postprandial Lipid Storage

Postprandial GIP acts together with elevated Insulin to participate in nutrient handling by adipose tissue and can promote fatty acid uptake, Triglyceride synthesis, and lipid storage. This process mainly occurs during the short postprandial window and is fundamentally a normal physiological program that transfers excess circulating nutrients into storage tissues. It should not be simply interpreted as GIP continuously promoting obesity.

4.2 Long-Acting GIPR Agonism Alters Long-Term Energy Balance

After long-acting GIPR agonists continuously act on central feeding networks, they can reduce daily Food Intake and total Energy Intake. Even if GIP-related lipid storage still occurs during the short postprandial period, as long as energy intake remains below expenditure over weeks to months, Triglyceride stores in adipose tissue will still be mobilized and Fat Mass will decrease. Short-term postprandial energy storage and long-term body-fat reduction occur on different metabolic timescales.

5 Long-Acting GIPR Agonism and Receptor Functional Adaptation

5.1 Functional Desensitization of GIPR

(1) Attenuation of Proximal Signaling

Sustained GIPR stimulation can reduce effective coupling between the receptor and Gs proteins and alter cAMP-regulatory components such as Adenylate Cyclase and Phosphodiesterase. After long-term agonism, the same degree of repeated stimulation may produce lower cAMP and downstream functional responses.

(2) Changes in Receptor Trafficking

Sustained agonism can also be accompanied by GIPR phosphorylation, internalization, and recycling. Functional desensitization does not require complete disappearance of GIPR from the cell surface; even when receptors remain present, they may show reduced G-protein coupling efficiency.

(3) Differences in Tissue Adaptation

The degree of receptor adaptation is not completely identical among β cells, AP-related GIPR neurons, and hypothalamic GIPR neurons. Chronic GIPR agonism produces tissue-specific sustained activation and functional adaptation rather than placing the entire organism uniformly into a low-GIPR-activity state.

5.2 Difference Between Chronic Agonism and Pharmacological Antagonism

Chronic GIPR agonism produces functional adaptation on the basis of sustained ligand binding and receptor activation, whereas GIPR antagonism directly reduces effective activation of the receptor by endogenous GIP. The two differ in receptor state, key brain regions involved, and neural-network output. Functional desensitization may participate in long-term GIPR pharmacology, but GIPR agonism and antagonism cannot be interpreted as the same mechanism.

6 Weight-Loss Mechanisms of GIPR Antagonism

6.1 Reduction of Hypothalamic GIPR Signaling

Hypothalamic GIPR continuously receives endogenous GIP and nutrient-state-related inputs and participates in setting the responsiveness of feeding networks to other satiety hormones. When a GIPR antagonist reduces this input, the excitation-inhibition relationship of some neural circuits changes, allowing other weight-loss signals to generate greater functional output.

6.2 Enhancement of GLP-1R-Mediated Food-Intake Suppression

GLP-1R agonists can directly activate central satiety networks and reduce Food Intake, whereas GIPR antagonists do not need to reproduce the same satiety signal. After some hypothalamic GIPR input is reduced, GLP-1R-related suppression of food intake can gain greater network amplification, allowing GLP-1R agonism to produce more pronounced reductions in food intake and body weight.

6.3 Enhancement of Amylin-Related Satiety Signaling

The gain-enhancing effect of GIPR antagonism is not limited to GLP-1R. After hypothalamic GIPR signaling is reduced, Amylin-related satiety effects can also be enhanced, indicating that GIPR may lie within a central regulatory level where multiple satiety signals converge. The pharmacological significance of GIPR antagonists therefore extends from simply blocking GIP to altering the sensitivity of feeding networks to other weight-loss signals.

7 Mechanistic Differences Between GIPR Agonism and Antagonism

7.1 Levels of Action of the Two Pharmacological Strategies

GIPR agonists mainly utilize the pancreatic islet and central signals that GIPR itself can generate, with hindbrain/AP-related GIPR directly participating in food-intake suppression. GIPR antagonists, in contrast, act more through reducing hypothalamic GIPR signaling and increasing the weight-loss gain of GLP-1R- or Amylin-related satiety pathways. Both approaches can ultimately converge on reduced Energy Intake and body weight, but the upstream receptor states and key central regions are different.

Table 1 Major Mechanistic Differences Between GIPR Agonism and Antagonism

7.2 Brain-Region Differences and the Agonism-Antagonism Phenomenon

Mouse studies indicate that GIPR agonism and antagonism can produce similar body-weight endpoints not because the two pharmacological interventions generate the same receptor state, but because GIPR in different brain regions performs different functions. Hindbrain GIPR, particularly in the AP, mainly mediates the direct food-intake suppression produced by exogenous GIPR agonists, whereas hypothalamic GIPR participates in the enhancement of weight-loss responses to GLP-1R and amylin receptor agonists during GIPR antagonism.

8 Representative GIPR-Related Drugs

8.1 Tirzepatide

(1) GIPR/GLP-1R Dual-Receptor Agonism

Tirzepatide is a long-acting GIPR/GLP-1R dual-receptor agonist in which a single peptide molecule provides activity at both incretin receptors. Its long-acting design allows sustained action at GIPR and GLP-1R over a prolonged pharmacokinetic window, placing pancreatic islet and central signaling under simultaneous regulation.

(2) Promotion of Glucose-Dependent Insulin Secretion

Tirzepatide simultaneously activates GIPR and GLP-1R in β cells. Both receptors can enhance cAMP-PKA/EPAC signaling and increase Ca²⁺-dependent Insulin granule exocytosis under high-Glucose conditions. Dual-receptor agonism therefore jointly amplifies the β-cell secretory process already initiated by glucose.

(3) Suppression of Food Intake and Enhancement of Satiety

GLP-1R can generate a strong central satiety signal, while GIPR further acts on GIPR-related feeding neural networks. The central nodes involved in the two receptors overlap but are not completely identical. Therefore, the anorectic pharmacology of Tirzepatide cannot be simplified to GLP-1R being responsible for feeding while GIPR is responsible only for Insulin.

(4) Pharmacological Positioning of the GIPR Component

Tirzepatide directly utilizes the pancreatic islet and central effects generated by GIPR agonism and combines them synergistically with GLP-1R. It represents a weight-loss drug design strategy based on actively enhancing GIPR signaling.

8.2 Maridebart Cafraglutide

(1) Combination of GIPR Antagonism and GLP-1R Agonism

Maridebart Cafraglutide integrates GIPR antagonism and GLP-1R agonism within the same long-acting molecular system. The GLP-1R component continuously provides direct satiety and metabolic signals, whereas the GIPR component reduces effective activation of the receptor by endogenous GIP.

(2) Enhancement of GLP-1R-Related Weight-Loss Effects

GLP-1R agonism provides the major food-intake-suppressing effect. Mechanistic studies in mice indicate that GIPR antagonism can enhance the weight-loss response to GLP-1R agonism through hypothalamic GIPR-related mechanisms; however, this specific brain-region mechanism has not been established as the confirmed mechanism of Maridebart Cafraglutide in humans.

(3) Pharmacological Differences From Tirzepatide

Tirzepatide increases GIPR activity, whereas Maridebart Cafraglutide decreases GIPR activity. The former directly utilizes the pancreatic islet and central effects of GIPR, while the latter uses GIPR antagonism to enhance other weight-loss pathways. These represent opposite directions of GIPR pharmacology that can both be used for weight loss.

8.3 Retatrutide

(1) GIPR/GLP-1R/GCGR Triple-Receptor Agonism

Retatrutide has agonist activity at GIPR, GLP-1R, and GCGR simultaneously. GIPR and GLP-1R mainly provide pancreatic islet and central nutrient regulation, while GCGR further increases hepatic substrate mobilization and energy metabolism, extending the overall pharmacology from feeding and pancreatic function to hepatic substrate utilization.

(2) Promotion of Glucose-Dependent Insulin Secretion

GIPR and GLP-1R jointly enhance cAMP signaling in β cells and increase Insulin secretion under Glucose-stimulated conditions. This effect can provide a certain degree of functional balance against GCGR-mediated increases in hepatic glucose output, making glucose homeostasis in triple-receptor pharmacology jointly determined by multiple receptors.

(3) Suppression of Food Intake and Enhancement of Satiety

GIPR and GLP-1R reduce feeding drive through partially distinct central neural nodes, allowing the triple-agonist system to maintain strong control of energy intake while adding the metabolic effects of GCGR.

(4) Relative Receptor Activity Determines Overall Pharmacology

The key to triple-receptor drugs is not simply simultaneous activation of three targets but the relative potency among GIPR, GLP-1R, and GCGR. Excessive GCGR activity may increase hepatic glucose output, whereas insufficient GIPR and GLP-1R activity may fail to adequately maintain pancreatic and feeding regulation. Final pharmacological efficacy depends on the balance among the three receptor signals.

Table 2 Pharmacological Strategies of Representative GIPR-Related Drugs

9 Key Experiments in GIPR Weight-Loss Research

9.1 Receptor Pharmacology Evaluation

GIPR uses Gs-cAMP as its major proximal signal. Research should first determine whether a candidate molecule acts as an agonist, partial agonist, or antagonist at GIPR. cAMP, EC₅₀, and Emax can be used to describe basic receptor pharmacology. For multi-receptor molecules such as Tirzepatide and Retatrutide, activity at each target receptor also needs to be evaluated separately to determine the relative contribution of GIPR to the overall pharmacological effect.

9.2 Pancreatic Islet and Feeding Functions

The two most representative functional endpoints in GIPR research are glucose-dependent Insulin secretion and Food Intake. The former reflects β-cell GIPR function, whereas the latter more directly corresponds to central feeding effects. Body Weight is an integrated phenotype resulting from the long-term accumulation of multiple pharmacological effects and should be interpreted together with Food Intake and Body Composition.

9.3 Agonism, Antagonism, and Multi-Receptor Contributions

GIPR agonist research focuses on direct GIPR signaling and hindbrain/AP-related suppression of food intake. When GIPR antagonists are combined with GLP-1R or Amylin pathways, attention should instead be given to hypothalamic GIPR and synergistic gain. Receptor-specific blockade, loss-of-function approaches, and comparisons of receptor potency are core strategies for distinguishing these mechanisms.

10 Research Products Related to GIPR-Mediated Weight Loss

10.1 GIPR Ligands and Multi-Receptor Pharmacology Research

10.2 Evaluation of GIPR Signaling and Pancreatic Islet Function

10.3 Evaluation of Central Feeding and Adipose Tissue Responses

There is no single answer of either agonism or antagonism for GIPR-mediated weight loss. GIPR agonism mainly utilizes the receptor’s own pancreatic islet and hindbrain feeding-regulatory effects, whereas GIPR antagonism acts more by enhancing satiety signals such as GLP-1R and Amylin through hypothalamic networks. Tirzepatide, Maridebart Cafraglutide, and Retatrutide demonstrate how different drug systems exploit the bidirectional pharmacological characteristics of GIPR and also make GIPR a metabolic target with distinctive value in multi-receptor weight-loss drug design.

For more related articles, please see below:

[1] Exendin-4 and Alzheimer’s Disease

[2] Glucose measurement experiment

[3] A Detailed Guide to the Construction of Animal Models for Metabolic Diseases

[4] Linking Alzheimer’s Disease and Insulin Signaling

[5] Metformin